These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 17997145

  • 1. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
    Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL.
    Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma.
    Einstein MH, Frimer M, Kuo DY, Reimers LL, Mehta K, Mutyala S, Huang GS, Hou JY, Goldberg GL.
    Gynecol Oncol; 2012 Jan; 124(1):21-5. PubMed ID: 22035806
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [Abstract] [Full Text] [Related]

  • 9. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
    Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, Villà S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A, Rare Cancer Network.
    Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The importance of chemotherapy and radiation in uterine papillary serous carcinoma.
    Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U.
    Gynecol Oncol; 2011 Dec; 123(3):542-7. PubMed ID: 21963091
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN, Asmar L, Messing MJ, Street DG, Pippitt CH, Bailey CL, Savage J, Young JA.
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [Abstract] [Full Text] [Related]

  • 13. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN, von Gruenigen V, Gibbons H, Abushahin F, Starks D, Markman M, Belinson J, Rose P.
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [Abstract] [Full Text] [Related]

  • 14. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
    Thomas MB, Mariani A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC.
    Gynecol Oncol; 2007 Nov; 107(2):186-9. PubMed ID: 17688926
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial.
    Frimer M, Miller EM, Shankar V, Girda E, Mehta K, Smith HO, Kuo DYS, Goldberg GL, Einstein MH.
    Int J Gynecol Cancer; 2018 Nov; 28(9):1781-1788. PubMed ID: 30371562
    [Abstract] [Full Text] [Related]

  • 19. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
    Rauh-Hain JA, Growdon WB, Schorge JO, Goodman AK, Boruta DM, McCann C, Horowitz NS, del Carmen MG.
    Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.